Abstract
Increased longevity has been achieved by genetic and environmental manipulations in model organisms, from nematodes to mammals. Genes that can extend life span when altered are referred to as “gerontogenes.” The last several years have seen a dramatic increase in the number of identified gerontogenes (approximately seventy-four). The vast majority of these genes have been identified in the nematode, Caenorhabditis elegans. These genes include age-1 (a phosphatidylinositol 3-OH kinase gene) and daf-2 (an insulin-like receptor gene), as well as genes mediating behavior, metabolism, reproduction and sensory perception. age-1 and daf-2 play a role in a hormonal signaling cascade similar to the mammalian insulin / IGF-1 pathways. The age-1 / daf-2 signal functions to shorten life span and repress the positive regulators of life span, daf-16 and old-1. Similarly, studies of Dwarf mice indicate that the growth hormone-IGF-1 axis may play a role in regulating longevity. Signals from certain tissues, such as sensory neurons and gonads, also regulate life span in C. elegans. The gonadal signal is dependent on the daf-9 cytochrome P450 gene and the daf-12 steroid receptor gene, implicating roles of steroid hormones in longevity. Moreover, increased resistance to intrinsic and environmental stresses [heat, UV, and reactive oxygen species (ROS)] has been shown to be intimately related to increased longevity in a variety of species. ROS scavengers, including superoxide dismutase (SOD) and SOD mimetics, can extend life span in the fruit fly Drosophila melanogaster and in C. elegans, respectively. We suggest that environmental and intrinsic stresses, depending on the evolutionary niche occupied by the species, are key factors that control life span and aging. In summary, cellular signals regulate systemic mechanisms that play a role in stress resistance and also affect longevity.
Current Genomics
Title: Regulation of Life Span in Model Organisms
Volume: 4 Issue: 1
Author(s): Shin Murakami and Thomas E. Johnson
Affiliation:
Abstract: Increased longevity has been achieved by genetic and environmental manipulations in model organisms, from nematodes to mammals. Genes that can extend life span when altered are referred to as “gerontogenes.” The last several years have seen a dramatic increase in the number of identified gerontogenes (approximately seventy-four). The vast majority of these genes have been identified in the nematode, Caenorhabditis elegans. These genes include age-1 (a phosphatidylinositol 3-OH kinase gene) and daf-2 (an insulin-like receptor gene), as well as genes mediating behavior, metabolism, reproduction and sensory perception. age-1 and daf-2 play a role in a hormonal signaling cascade similar to the mammalian insulin / IGF-1 pathways. The age-1 / daf-2 signal functions to shorten life span and repress the positive regulators of life span, daf-16 and old-1. Similarly, studies of Dwarf mice indicate that the growth hormone-IGF-1 axis may play a role in regulating longevity. Signals from certain tissues, such as sensory neurons and gonads, also regulate life span in C. elegans. The gonadal signal is dependent on the daf-9 cytochrome P450 gene and the daf-12 steroid receptor gene, implicating roles of steroid hormones in longevity. Moreover, increased resistance to intrinsic and environmental stresses [heat, UV, and reactive oxygen species (ROS)] has been shown to be intimately related to increased longevity in a variety of species. ROS scavengers, including superoxide dismutase (SOD) and SOD mimetics, can extend life span in the fruit fly Drosophila melanogaster and in C. elegans, respectively. We suggest that environmental and intrinsic stresses, depending on the evolutionary niche occupied by the species, are key factors that control life span and aging. In summary, cellular signals regulate systemic mechanisms that play a role in stress resistance and also affect longevity.
Export Options
About this article
Cite this article as:
Murakami Shin and Johnson E. Thomas, Regulation of Life Span in Model Organisms, Current Genomics 2003; 4 (1) . https://dx.doi.org/10.2174/1389202033350137
DOI https://dx.doi.org/10.2174/1389202033350137 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets Supramolecular Nanomedicine - An Overview
Current Drug Targets Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase
Current Clinical Pharmacology The Role of Quercetin, Flavonols and Flavones in Modulating Inflammatory Cell Function
Inflammation & Allergy - Drug Targets (Discontinued) Diabetic Retinopathy: Current and New Treatment Options
Current Diabetes Reviews A Simple Stability-Indicating LC-UV Method to Assay Sitagliptin Phosphate in Tablets
Current Analytical Chemistry Oxidative Stress and its Clinical Consequences: Relationship between Diabetes and Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prostate Cancer Gene Regulatory Network Inferred from RNA-Seq Data
Current Genomics The Effect of Devazepide (CCK-1 Receptor Blocker) on Food Intake Suppression Induced by Whey Protein and Glycomacropeptide in Wistar Rats
Current Nutrition & Food Science Recognition and Impact of Host-derived Molecules on Bacterial Cell-tocell Signalling Pathways
Medicinal Chemistry Vascular Pleiosynergy - Does It Really Work?
Current Vascular Pharmacology Antitumor Activities of Interleukin-27 on Melanoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design Role of Fibroblast Growth Factor Receptors in Astrocytic Stem Cells
Current Signal Transduction Therapy Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species
Current Pharmaceutical Design Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities
Current Pharmaceutical Design